Kidney transplant rejection trial halted before it began
NCT ID NCT02113891
First seen Nov 20, 2025 · Last updated Apr 25, 2026 · Updated 22 times
Summary
This study planned to test the drug eculizumab in kidney transplant patients who had signs of rejection not yet causing symptoms. The goal was to see if blocking part of the immune system could prevent long-term kidney damage. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCLINICAL ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.